Methods of reversing and preventing cardiovascular pathologies

• US 20030181520A1
• Filed: 11/12/2002
• Published: 09/25/2003
• Est. Priority Date: 11/09/2001
• Status: Abandoned Application

• Current Assignee: Atherogenics, Inc.
• Original Assignee: Atherogenics, Inc.
• Inventors: Glass, Mitchell, Tardif, Jean-Claude
• Application Number:
  US10/293,399
• Publication Number:
  US 20030181520A1
• Time in Patent Office: Days
• US Class Current: 514/548
• CPC Class Codes: A61K 31/225 Polycarboxylic acids
• CPC Class Codes: A61P 3/06 Antihyperlipidemics
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/02 Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The present invention is a method to increase the lumen diameter of a coronary blood vessel, in a mammal, particularly a human, that includes administering a compound of the formula

wherein x is defined as an integer between 1 and 4;

or a pharmaceutically acceptable salt, ester or prodrug thereof.

Claims

1. A method to prevent cardiovascular disease characterized by a decrease in lumen diameter comprising administering a therapeutically effective amount of a compound having the formula

2. The method of claim 1, wherein the compound is

3. The method of claim 1 or 2, wherein the mammal is human.

4. A method to reverse cardiovascular disease characterized by a decrease in lumen diameter comprising administering a therapeutically effective amount of a compound having the formula

5. The method of claim 4, wherein the compound is

6. The method of claim 4 or 5, wherein the mammal is a human.

7. A method to prevent progression of a cardiovascular disease characterized by a decrease in lumen diameter comprising administering a therapeutically effective amount of a compound to a mammal, wherein the compound having the formula

8. The method of claim 7 wherein the compound is

9. The method of claim 7 or 8, wherein the mammal is a human.

10. A method to prevent cardiovascular disease characterized by a decrease in lumen diameter comprising administering a therapeutically effective amount of a compound having the formula

11. The method of claim 10, wherein the compound is

12. The method of claim 10 or 11, wherein the mammal is human.

19. The method as in any one of claims 10-18, wherein the therapeutic agent is probucol.

20. The method as in any one of claims 10-18, wherein the therapeutic agent is statin.

21. The method as in any one of claims 10-18, wherein the therapeutic agent is an IBAT inhibitor.

13. A method to reverse cardiovascular disease characterized by a decrease in lumen diameter comprising administering a therapeutically effective amount of a compound having the formula

14. The method of claim 13, wherein the compound is

15. The method of claim 13 or 14, wherein the mammal is a human.

16. A method to prevent progression of a cardiovascular disease characterized by a decrease in lumen diameter comprising administering a therapeutically effective amount of a compound to a mammal, wherein the compound having the formula

17. The method of claim 16, wherein the compound is

18. The method of claim 16 or 17, wherein the mammal is a human.

22. A method to increase the lumen diameter of a blood vessel in a human, comprising administering an effective lumen diameter increasing amount of a compound having the formula: